Striving for a better future, Silenseed is dedicated towards developing drugs and drug delivery platforms that create a novel treatment for solid tumors. Harnessing new scientific horizons, we are developing solutions for untreated cancers and innovative ways for RNAi drug delivery.
Phase II Clinical Trial for Pancreatic Cancer –
Currently not recruiting
Motivated by the challenges facing RNAi delivery, Silenseed has developed a novel drug delivery platform – LODER™ (LOcal Drug EluteR), which enables the insertion of RNAi therapeutic pharmaceuticals directly into the core of solid tumors
With patients in mind – Silenseed is dedicated towards developing novel drugs that harness new scientific horizons developing solutions for untreated cancers
Israel-based Silenseed, a clinical-stage biopharmaceutical company, has announced that it has signed a Joint Venture Agreement with Guangzhou Sino-Israel...
Amotz Shemi, CEO, Silenseed will address ” Recent clinical progress with RNAi loaded KRAS-LODER for pancreatic tumor” on Thursday...
May 25, 2021, Modiin, Israel. Amotz Shemi, PhD, CEO of Silenseed will present in September 21-23, 2021 on: KRAS-LODER...
April 19, 2020, Modiin, Israel. Silenseed announced today the filing of a new patent application named INTRANASAL DRUG DELIVERY...
April 16, 2020, Modiin, Israel. Silenseed announced today the filing of a new provisional patent application named “DEVICES, COMPOSITIONS,...
Nov 24, 2019 Silenseed announced today the International Patent Application No.: PCT/IL2018/050560 USA Patent Application number: 15/326044 (applied in...
January 2, 2019 – Silenseed to present early Phase 2 clinical results in stage 3 pancreatic cancer. Presentation will...
Oct 4., 2018 – Silenseed announced the new website pancan-protact.com for the ongoing Phase II study named PROTACT. PROTACT,...
